2025年7月8日 ， 瑞士医疗科技公司 Aktiia 宣布，其 G0无袖带血压监测系统 获得美国食品药品监督管理局（FDA）510(k)批准。 这是全球首款被批准可作为非处方 （OTC）产品上市的无袖带血压监测可穿戴设备，标志着血压管理从传统袖带向无创、连续、可穿戴技术的转折点。 G0系统计划于 2026年 在美国上市，初期将通过零售药店、电商和医疗渠道销售，预计售价在300美元左右。此前，该系统已 获得CE认证，并 在欧洲多个国家以 Hilo品牌销售。 # 无袖带血压监 测的 核心突破 Aktiia G0系统（美国市场称为Hilo Band），核心技术基于 光体积描记法（PPG） ，通过佩戴在手腕上的光学传感器，捕捉血管随心跳产生的微小体积变化，结合自 研的 CALFREE算法 ，实时估算收缩压（SBP）与舒张压（DBP）。 传统的血压监测依赖充气袖带，虽然精准，但存在几个痛点：测量过程需要主动操作，患者往往难以坚持；袖带反复充气造成不适，特别是夜间监测干扰睡眠；测 量频率低，可能漏掉血压波动。 G0系统针对这些问题，做出了以下技术突破： 虽然精度略低于传统袖带设备，但在连续性和用户体验方面，G0系统实现 ...

"'融资贵'是我们企业普遍关心的问题，没想到明示试点工作帮我们省了1万多元的支出。"重庆某建筑 工程有限公司的负责人郑先生表示。通过与重庆农村商业银行巫溪支行共同填写《企业贷款综合融资成 本清单》，郑先生对不同信贷产品的综合融资成本有了更清晰的认识，也更加全面、清晰地了解了各个 环节的各项费用是否充分享受了优惠政策，还有哪些减免空间，切实做到"明底数"。最终，郑先生选择 了综合融资成本更低、更加匹配自身需求的信贷产品，将节省资金全部投入生产，生产效率不断提高。 2025年3月，中国人民银行重庆市分行启动明示贷款综合融资成本试点，重庆市巫溪县作为国家乡村振 兴重点帮扶县，首批参与试点。在中国人民银行万州分行巫溪营业管理部的指导下，试点银行机构精准 锚定实体经济融资痛点，以"穿透式成本披露+全链条费用明示+搭建沟通桥梁"联动，通过与企业共同 填写《企业贷款综合融资成本清单》，让企业融资成本不再"雾里看花"。截至5月末，共对567笔，2.54 亿元企业贷款进行综合融资成本明示，市场主体的获得感持续提升。 "以前办理贷款只知道贷款利率，其他费用明细一概不知，贷款明示让我们可以清楚地了解到所有费用 明细，保障了企业的知 ...

寻找下一个明星——港股通 2025 年 9 月调整名单预测 20250708 摘要 港股市场整体呈现震荡但缓慢上升的格局，盈利预期稳定、无风险利率 下降及高股息板块投资者增加是主要驱动因素。当前市场隐含股权风险 溢价约为 5.4%，情绪指标略有上行空间。 港股通对港股市场影响显著，港股通投资者贡献的成交量已达总成交量 的 25%，未来需重视港股通纳入标的带来的投资机会。低成本资金通过 港股通抬高指数估值，压低隐含 ERP 波动区间。 无风险利率环境下降将推动港股市场，美联储降息预期最早可能在 2025 年 9 月或第四季度实现。HIBOR 波动主要受短期 IPO 活动和派息 影响，对主流投资者资金成本影响相对间接。 公司被剔除出港股通通常对其股价产生较大压力，而被纳入港股通的公 司，其股价平均涨幅通常为正。关注哪些公司可能入通或出通，对投资 具有重要指导意义。 周六福受益于金价上涨和滞后需求释放，黄金珠宝销售额在社零全品类 中排名靠前，并保持双位数增长。公司聚焦下沉市场，全国性布局完善， 产品矩阵丰富，线上收入占比高。 Q&A 申万宏源对 2025 年下半年港股市场的策略观点是什么？ 根据申万宏源的半年度策略 ...

Group 1 - Sannuo Group expects a net loss of 100 million to 120 million yuan for the first half of 2025, a significant decline from a profit of 7.4 million yuan in the same period last year [1] - The company anticipates a net loss of 77 million to 95 million yuan after excluding non-recurring gains and losses [1] - Basic earnings per share are projected to be a loss of 0.2148 to 0.2578 yuan per share [1] Group 2 - Landai Technology is planning to transfer 18% of its shares, which may lead to a change in control [2] - The stock of Landai Technology has been suspended from trading since July 8, 2025, with an expected suspension period of no more than two trading days [2] Group 3 - Xinxin Co. announced that a senior executive plans to reduce their holdings by up to 750,000 shares, representing no more than 0.2971% of the total share capital [3] - The reason for the reduction is personal financial needs [3] Group 4 - Biyimi plans to reduce its shares by a total of up to 3% by two shareholders, with one shareholder planning to reduce up to 139.68 million shares (2.00%) and the other up to 69.84 million shares (1.00%) [4] - The reason for the reduction is also personal financial needs [4] Group 5 - Changxin Bochuang announced that shareholders plan to reduce their holdings by up to 2.95%, totaling 8.6 million shares [6] - The reason for the reduction is personal financial needs [6] Group 6 - Tianci Materials plans to publicly issue H-shares and apply for listing on the Hong Kong Stock Exchange [9] Group 7 - Sanxiang Impression announced the termination of a previous equity transfer agreement, following a request from its controlling shareholder [10] Group 8 - Zhongke Technology has decided to terminate its plan to issue shares for asset acquisition and related fundraising due to changes in market conditions [12] Group 9 - Hangcha Group's subsidiary plans to acquire 99.23% of Guozu Robot's shares through capital increase [14] Group 10 - Xishan Technology plans to increase its holdings in the company by no less than 5 million and no more than 10 million yuan [19] Group 11 - New Hope reported sales of 1.33 million pigs in June, a year-on-year increase of 3.38% [21] - The sales revenue was 1.871 billion yuan, a year-on-year decrease of 19.14% [21] Group 12 - Auhua Endoscope announced that two shareholders plan to reduce their holdings by up to 1.92% [18] Group 13 - Star Source Material has submitted an application for H-share issuance and listing [18] Group 14 - Yilian Technology plans to invest 20 million yuan to establish a partnership with professional institutions [30]

Core Insights - The report "Top 50 R&D Effective A-share Listed Companies" was independently developed by Gaoke Think Tank, focusing on the efficiency of innovation in A-share listed companies [2] - The selected 50 companies have an average R&D efficiency of 1.66 times, representing the top level in China's hard technology sector [2] Selection Criteria - **Financial Thresholds**: Companies must have revenue greater than 100 million yuan, non-recurring net profit greater than 10 million yuan, main business net profit margin greater than 10%, revenue and profit growth both exceeding 10%, and asset-liability ratio less than 70% [2] - **Innovation Hard Indicators**: R&D intensity (R&D expenses/revenue) must be greater than 10%. The final ranking is based on the R&D effectiveness index (non-recurring net profit/R&D expenses) in descending order [2] Company Profile - **Industry Distribution**: The report covers 22 sub-sectors in hard technology, including industrial control equipment, integrated circuit design, medical devices, and photovoltaic processing equipment [2] - **Representative Companies**: Leading companies include Bochao Electronics, Lanke Technology, and Dier Laser [2] Average Data - The average revenue of the selected companies is 1.005 billion yuan, with a non-recurring net profit of 208 million yuan, a main business net profit margin of 22.35%, and an R&D intensity of 13.98% [3] Methodological Advantages - **Objectivity**: The selection process uses anonymous selection and mathematical modeling to eliminate human intervention [3] - **Innovation**: The report breaks away from traditional ranking methods based on scale or profit, introducing a new dimension of "R&D effectiveness" [4] - **Policy Alignment**: The report aligns with national strategies to enhance the overall efficiency of the innovation system and supports the development of new productivity [4]

Group 1 - Mianyang has 20 national-level defense research institutes and 264 provincial and national innovation platforms, with 29 academicians and over 86,000 high-level talents introduced in the past three years [1][2] - The city has established 41 municipal academician (expert) workstations through collaboration with 12 academicians and over 110 high-level experts since 2012 [3][2] - Mianyang is focusing on technology innovation to empower high-quality industrial development, exemplified by the world's smallest linear vibration motor produced by Anhe Precision Electronics [1][2] Group 2 - The "enterprise proposes, government sets, and collaboration solves" research mechanism has been established in Youxian District, leading to breakthroughs such as the nitrogen zirconium sensor and the first proton therapy device [2][3] - A public platform for pilot testing services has been launched, significantly reducing the time for precision parts sample production from one month to three days [4][5] - Mianyang is constructing a comprehensive support system for pilot testing, including a 100 million yuan pilot fund and a 50 million yuan "first investment, then equity" special fund [5][6] Group 3 - The city is focusing on integrating technology innovation into industrial development, with the establishment of several innovation centers and laboratories aimed at resource sharing and deep collaboration [7][8] - Southwest University of Science and Technology has projects selected for the "enterprise finds technology" initiative, focusing on wind turbine blade protection in extreme environments [8]

Core Viewpoint - The company has a strong shareholder backing and rich resources, focusing on expanding its business through acquisitions and diversifying into three main sectors: medical, optical, and electrical [1] Group 1: Company Overview - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in 2012 and has since expanded its business through acquisitions in 2015 and 2018 [1] - Yizhuang Investment became the controlling shareholder in 2021, with a registered capital of 18.8 billion yuan and managed assets of 145.1 billion yuan [1] Group 2: Business Segments - The company focuses on the entire value chain of digital pathology, building an integrated ecosystem covering R&D, manufacturing, sales, and services [2] - The optical division has over 30 years of experience, specializing in optical microscopes and related systems, with a customer network spanning 109 countries [3] - The smart electrical business specializes in epoxy insulation components, covering voltage levels from 10kV to 1,100kV, and has established long-term partnerships with leading global companies [4] Group 3: Financial Performance and Projections - The company anticipates revenue growth from 1.477 billion yuan in 2025 to 1.852 billion yuan in 2027, with corresponding net profits increasing from 174 million yuan to 260 million yuan [5] - The earnings per share (EPS) are projected to rise from 0.34 yuan in 2025 to 0.50 yuan in 2027, reflecting a stable growth outlook [5]

腾讯出手了。 近日，晨壹基金旗下上海晨峦企业管理合伙企业（有限合伙）发生工商变更，新增广西腾讯创业投资有限公司、无锡晨壹成长股权投资基金（有限合伙）、 厦门金圆展鸿二期股权投资合伙企业（有限合伙）、珠海众烨投资企业（有限合伙）等为合伙人。 晨壹基金的掌门人——刘晓丹曾是华泰联合证券的灵魂人物，操刀不少经典案例，被称为"并购女王"。2019年，刘晓丹成立晨壹基金管理（北京）有限公 司，完成私募股权、创业投资基金管理人备案登记，任晨壹基金的管理合伙人，聚焦并购领域。 腾讯出手 天眼查显示，上海晨峦企业管理合伙企业（有限合伙）成立于2022年2月，执行事务合伙人为晨壹红启（北京）咨询有限公司，经营范围含企业管理、企业管 理咨询、信息咨询服务。该合伙企业由晨壹红启（北京）咨询有限公司、北京晨壹并购基金（有限合伙）等共同出资成立。 今年7月，上海晨峦企业管理合伙企业（有限合伙）的合伙人名单新增加了广西腾讯创业投资有限公司、无锡晨壹成长股权投资基金（有限合伙）、厦门金圆 展鸿二期股权投资合伙企业（有限合伙）、珠海众烨投资企业（有限合伙）、深圳舟益管理咨询合伙企业（有限合伙）等，注册资金由4.61亿元增至11.61亿 元。 ...

Summary of Key Points Core Viewpoint - The Hong Kong Stock Exchange (HKEX) saw 11 companies submit applications for listing from June 30 to July 6, with no companies passing the listing hearing during this period. Additionally, 7 companies initiated their public offerings, and 5 new stocks were listed. Group 1: Companies Submitting Applications - Puxiang Health Holdings Limited is a leading provider of integrated medical and elderly care services in North China, ranking second in revenue among its peers and first in revenue growth from 2022 to 2024 [2] - Magnesium Health Technology Co., Ltd. focuses on innovative payment solutions for medical expenses, being the largest provider of innovative health insurance solutions in China by policy count [3] - Yangtuo Technology Inc. operates a trading and service platform for home care and nutrition products, holding a 10.1% market share in the low-tier market [4] - Xiamen Ruiwei Information Technology Co., Ltd. specializes in image intelligent analysis products and solutions, leveraging machine learning and computer vision technologies [5] - Zijin Gold International Limited is a leading global gold mining company, ranking ninth in gold reserves and eleventh in production as of 2024 [6] - EVE Energy Co., Ltd. is a leading lithium battery platform company, ranking first in China for consumer cylindrical battery shipments and second globally for energy storage battery shipments [7] - Zhejiang Yifei Intelligent Technology Co., Ltd. is a leading industrial robotics company in China, focusing on the light industry [8] - ChipMight Semiconductor Technology (Hangzhou) Co., Ltd. is a leading power semiconductor company, ranking second in the global OLED display PMIC market [9] - Beijing Tongrentang Medical Investment Co., Ltd. is the largest non-public Chinese medicine hospital group by outpatient and inpatient visits [11] - Shandong Linglong Tire Co., Ltd. is the largest OE tire manufacturer in China and the third largest globally [12] - Magnesium Holdings Limited is an innovative automotive technology company focused on AI-driven integrated domain control solutions [13] Group 2: Public Offerings and New Listings - Seven companies initiated their public offerings, including Anjii Foods, which had a subscription rate of 44.2 times for its public offering [14][15] - Other companies like Lens Technology and Fortior also initiated their public offerings with significant interest from cornerstone investors [16][19] - Five new stocks were listed, including Yunzhisheng, which saw a closing price increase of 44.59% on its first day [20][21][22][23] Group 3: Market Insights - The Hong Kong Stock Exchange raised over HKD 107 billion in the first half of 2025, with a 20% increase in the Hang Seng Index [24] - The biopharmaceutical sector has seen a resurgence, with 10 companies successfully listing in the first half of 2025, compared to only 12 for the entire previous year [25][26] - The total fundraising amount for the biopharmaceutical sector reached HKD 15.6 billion in the first half of 2025, indicating strong market interest [26][27]

Core Viewpoint - The article highlights the advancements in breast ultrasound technology through the introduction of Smart Breast, an AI-assisted feature by Mindray, aimed at improving diagnostic efficiency and accuracy in breast imaging [2][4]. Group 1: Smart Breast Technology - Smart Breast utilizes deep learning algorithms trained on a large dataset of breast ultrasound images to perform automatic lesion detection and segmentation [3]. - The technology shows high sensitivity (92%) and specificity (85%) in detecting breast masses, outperforming traditional manual ultrasound analysis [4]. - Smart Breast is particularly effective in dense breast tissue, increasing the likelihood of detecting small lesions (<1 cm) [4]. Group 2: Clinical Impact - Clinical feedback indicates that Smart Breast can reduce ultrasound examination time by approximately 30%, making it especially useful for radiologists in high-volume breast screening [4]. - The system can intelligently identify suspicious lesions, automatically delineate their boundaries, and measure key parameters, aiding in disease progression monitoring and surgical planning [6]. Group 3: Company Overview - Mindray Medical, founded in 1991 and headquartered in Shenzhen, is a leading global medical device supplier with a diverse product range including patient monitoring, in-vitro diagnostics, and medical imaging systems [5]. - In 2024, Mindray reported an annual revenue of 36.73 billion yuan, a year-on-year increase of 5.1%, with a net profit of 11.67 billion yuan, reflecting a 0.7% growth [5].